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Identity 
Other names: BGCAN; Betaglycan; TbetaRIII; 
TGFR-3 




The TGFBbetaR3 gene encodes 16 exons. 
Transcription 
The human TGFBR3 gene has two promoters, a 
proximal promoter and a distal promoter and produces 
a 4.2 kb mRNA. TGF-beta1 has been demonstrated to 
down regulate TbetaRIII expression through direct 
inhibition of the proximal TbetaRIII promoter. 
Protein 
Description 
TbetaRIII is an 853 amino acid transmembrane 
proteoglycan, which contains a short 41 amino acid 
cytoplasmic domain. TbetaRIII is a proteoglycan which 
contains glycosaminoglycan (GAG) side chain 
modifications (S535 and S546) composed of heparin 
and chondroitin sulfate. The TbetaRIII core has 
predicted molecular weight of 100 kDa, however fully 
processed TbetaRIII migrates at an apparent molecular 
weight of 180 to 300 kDa due to these 
glycosaminoglycan post-translational modifications. 
TbetaRIII contains a class I PDZ binding motif and a 
beta-arrestin2 interacting motif in the cytoplasmic 
domain, as well as a ZP-1 (zona pellucida) domain in 
the extracellular domain. The cytoplasmic domain of 
TbetaRIII is phosphorylated by TbetaRII. TbetaRIII 
also undergoes ectodomain shedding to produce soluble 
TbetaRIII (sTbeta-RIII). 
Expression 
TbetaRIII is ubiquitously expressed on nearly all cell 
types. Some cell types, including endothelial and 
hematopoietic cells, appear to have low to no TbetaRIII 
expression. The level of TbetaRIII expression is cell 
type specific. 
Localisation 
TbetaRIII exists as a transmembrane protein in the cell 
membrane and as a secreted protein, known as soluble 
TbetaRIII (sTbetaRIII), which can be detected in the 
extracellular matrix and serum. 
Function 
TbetaRIII is a member of the TGF-beta superfamily 
signaling pathways, which have essential roles in 
mediating cell proliferation, apoptosis, differentia-tion, 
and migration in most human tissues. TbetaRIII is the 
most abundantly expressed TGF-beta superfamily 
receptor and functions as a TGF-beta superfamily co-
receptor, by binding the TGF-beta superfamily 
members, TGF-beta1, TGF-beta2, or TGF-beta3, 
inhibin, BMP-2, BMP-4, BMP-7, and GDF-5 and 
presents these ligand to their respective signaling 
receptors to activate or repress (in the case of inhibin) 
TGF-beta1, BMP, or activin signaling to the Smad 
transcription factors. For example, in the case of TGF-
beta1, 2, or 3, Tbeta-RIII presents ligand to the TGF-
beta type II receptor (TbetaRII). Once bound to ligand, 
TbetaRII then recruits and transphosphorylates the 
TGF-beta type I receptor (TbetaRI), activating its 
kinase function and leading to the phosphorylation of 
Smad2/3. Phosphorylation of Smad2 and Smad3 leads 
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to formation of a complex with Smad4, and 
accumulation of this complex in the nucleus, where 
along with co-activators and co-repressors they regulate 
the transcription of genes involved in proliferation, 
angiogenesis, apoptosis, and differen-tiation. In 
addition to regulating receptor mediated Smad 
signaling, TbetaRIII also mediates ligand dependent 
and independent p38 pathway signaling. TbetaRIII can 
also undergo ectodomain shedding to generate soluble 
TbetaRIII (sTbetaRIII), which binds and sequesters 
TGF-beta superfamily members to inhibit their 
signaling. Although sTbetaRIII expression has been 
demonstrated to correlate with the cell surface 
expression of TbetaRIII, little is known about the 
regulation of sTbetaRIII production. The regulation 
TbetaRIII expression is sufficient to alter TGF-beta 
signaling. The cytoplasmic domain of TbetaRIII 
interacts with GIPC, a PDZ-domain containing protein, 
which stabilizes TbetaRIII cell surface expression and 
increases TGF-beta signaling. The cytoplasmic domain 
of TbetaRIII is also phosphorylated by TbetaRII, which 
results in TbetaRIII binding to the scaffolding protein 
beta-arrestin2. The TbetaRIII/ beta-arrestin2 interaction 
results in the co-internalization of beta-
arrestin2/TbetaRIII/Tbeta RII and the down-regulation 
of TGF-beta signaling. During development TbetaRIII 
has an important role in the formation of the 
atrioventricular cushion in the heart. Consistent with an 
important role for TbetaRIII during development, 
TGFbetaR3 null mice are embryonic lethal due to heart 
and liver defects. TGFbetaR3 has been recently 
identified as a tumor suppressor in multiple types of 
human cancers, including breast, lung, ovarian, 
pancreatic and prostate cancer. The loss of TGFbetaR3 
in these cancer types correlates with disease 
progression, and results in increased motility and 
invasion in vitro and increased invasion and metastasis 
in vivo. 
Homology 
TbetaRIII shares several regions of homology with the 
superfamily co-receptor, endoglin, with 2 regions of 
homology in the extracellular domain, a large domain 
near the amino terminus with 21% homology, and a 
shorter domain near the sites of GAG modification with 
50% homology. In addition, their cytoplasmic domains 
share 70% homology. 
Mutations 
Somatic 
Mutations in TbetaRIII have not been found in human 
cancers, although inactivating mutations in other 








Breast cancer is the second leading cause of cancer 
death in women, exceeded only by lung cancer in the 
United States. Types of breast cancer include ductal 
carcinoma in situ (DCIS), lobular carcinoma in situ 
(LCIS), and invasive or infiltrating ductal carcinoma 
(IDC). 
Prognosis 
The current five year survival rate for breast cancer is 
98% for localized cancer, 80% for regional cancer, and 
27% for metastatic disease with distant spread. 
Oncogenesis 
TbetaRIII loss occurs relatively early in mammary 
carcinogenesis, with loss beginning in the pre-invasive 
state of DCIS. The degree of TbetaRIII loss correlates 
with breast cancer progression and with a decrease in 
patient survival. TbetaRIII loss in breast cancer is due 
to LOH (loss of hetero-zygosity) at the TGFbetaR3 
gene locus and potential transcriptional down 
regulation of TbetaRIII by increased levels of TGF-
beta in the tumor microenvironment. Restoring 
TbetaRIII expression inhibits tumor invasion, 
angiogenesis, and metastasis in vivo. TbetaRIII 
functions, in part, through the production of sTbetaRIII 
by ectodo-main shedding, which antagonizes TGF-beta 
signaling, leading to a decrease in invasiveness and 
angiogenesis in vivo. In addition, TbetaRIII functions 
as a tumor suppressor in non-tumorigenic mammary 
epithelial cells through the inhibition of NFkappa-B 
mediation repression of E-cadherin. Loss of TbetaRIII 
in non-tumorigenic mammary epithelial cells leads to 
increased invasive capa-bilities due to up-regulated 
NFkappa-B activity and loss of E-cadherin expression. 
Non-small Cell Lung Cancer (NSCLC) 
Disease 
Lung cancer is the leading cause of death of both males 
and females in the United States. Non-small cell lung 
cancer accounts for 87% of all lung cancers. 
Prognosis 
The five year survival rate for all stages of lung cancer 
is 15%. The survival rate is 49% for localized disease; 
however few cases are identified at this stage. 
Oncogenesis 
TbetaRIII has been characterized as a tumor suppressor 
in non-small cell lung cancer. Expression of TbetaRIII 
is lost in the majority of non-small cell lung cancer 
(NSCLC) at both the mRNA expression level and the 
protein level. Loss of heterozygosity (LOH) occurs in 
38.5% of NSCLC human specimens and correlates with 
decreased TbetaRIII expression, suggesting that LOH 
is one mechanism of loss of TbetaRIII expression. Loss 
of TbetaRIII expression correlates with NSCLC  
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progression and increasing tumor grade, with a trend 
towards decreased survival. The loss of TbetaRIII 
results in a functional increase in cellular migration, 
invasion, and anchorage independent growth of lung 
cancer cells. TbetaRIII regulates cellular invasion and 
motility in lung cancer in part through the generation of 




Prostate cancer is the most commonly diagnosed 
malignancy in men and the third leading cause of 
cancer-related deaths among men in the United States. 
Prognosis 
The five year survival rate for all stages of prostate 
cancer is near 99%. The five year survival rate for local 
and regional disease approaches 100%. 
Oncogenesis 
TbetaRIII has been characterized as a tumor suppressor 
in prostate cancer. Expression of TbetaRIII is lost or 
decreased in the majority of human prostate cancers at 
both the mRNA and protein level, due to the loss of 
heterozygosity at the TbetaRIII locus and epigenetic 
regulation of the TbetaRIII promoter. Loss of TbetaRIII 
correlates with advancing tumor stage and an increased 
probability of prostate-specific antigen (PSA) 
recurrence. Restoring TbetaRIII expression in prostate 
cancer cells decreases cell motility and cell invasion in 
vitro and tumorigenicity in vivo. The loss of TbetaRIII 
is a common event in human prostate cancer cells and 
is important for tumor progression through effects on 
cell motility, invasiveness, and tumorigenicity. 
Ovarian Cancer 
Disease 
Ovarian cancer is the fifth leading cause of cancer 
death among women in the United States. The majority 
of ovarian cancers are ovarian epithelial carcinomas or 
malignant germ cell tumors. 
Prognosis 
The overall five year survival rate is 45% for ovarian 
cancer. The five year survival rate is 70% for patients 
with regional disease. However the lack of effective 
treatments for metastatic disease and the aggressive 
nature of this disease results in a 30% survival rate for 
those with metastatic disease. 
Oncogenesis 
TbetaRIII has been characterized as a tumor suppressor 
in ovarian cancer. TbetaRIII expression is decreased or 
lost in epithelial derived ovarian cancer at both the 
mRNA and protein level due to epigenetic silencing 
which is progressive with increasing tumor grade. 
TbetaRIII inhibits ovarian cancer cell invasiveness and 
migration. TbetaRIII specifically promotes the anti-
migratory action of inhibin and inhibin-mediated 
repression of matrix metalloproteinases, which play a 




Pancreatic cancer is the fourth leading cause of cancer 
death in the Unites States, with incidence levels closely 
matching the death rate. The majority of pancreatic 
cancers are adenocarcinomas, while endocrine 
pancreatic cancer is rare. 
Prognosis 
Pancreatic cancer has a low survival rate, with the 
median survival rate being four to six months and a five 
year survival rate of less than 5%. The 5 year survival 
rate for local disease is 20%. This low survival rate is 
due to delayed diagnosis caused by a lack of symptoms 
until the cancer is locally invasive or metastatic, a lack 
of effective screening tests, and ineffective treatments. 
Oncogenesis 
TbetaRIII may function as a tumor suppressor in 
pancreatic cancer. The genomic locus for TGFBR3 is 
deleted in 49% of human pancreatic cancers. Loss of 
TbetaRIII expression at the message and protein level 
correlates with worsening tumor grade in human 
pancreatic cancer specimens. In a pancreatic model of 
epithelial to mesenchymal transition (EMT), TbetaRIII 
expression is lost at the mRNA and protein levels. The 
loss of TbetaRIII protein expression occurs before the 
loss of E-cadherin and cytoskeletal reorganization, both 
markers of early EMT, and correlates with increased 
invasion and motility, hallmarks of EMT. The ability of 
TbetaRIII to suppress invasion and motility is partially 
mediated by sTbetaRIII. 
Renal Cell Carcinoma (RCC) 
Disease 
RCC is the most common form of kidney cancer. There 
are several subtype of RCC including Clear Cell RCC, 
Papillary RCC, Chromophobe RCC, and Collecting 
Duct RCC. 
Prognosis 
The 5 year survival rate for all stages of renal cell 
carcinoma is 65.5%. There is a lack of effective 
treatments for metastatic RCC and the 5 year survival 
rate is 9.5% for metastatic disease. 
Oncogenesis 
Loss of TbetaRIII at both the mRNA and the protein 
level occurs in all RCC tumor stages. Loss of TbetaRIII 
RNA expression is an early event in RCC and leads to 
a partial loss of TGF-beta responsiveness and 
attenuation of TGF-beta signaling. The sequential loss 
of TbetaRII after TbetaRIII loss leads to complete 
TGF-beta resistance and a more aggressive, metastatic 
RCC phenotype. Restoring TbetaRIII expression in the 
presence of TbetaRII, leads to enhanced TGF-beta 
signaling, restoration of growth inhibition, and the loss 
of anchorage independent growth over that observed 
with TbetaRII alone. 
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